Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonmyeloablative PBSC Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies
NCT03187756Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- Jun 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in hematologic malignancy, sponsored by NYU Langone Health. Started Jun 2017; status: terminated.
02
Drugs
cyclophosphamide
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT03187756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03187756.